| Name | K-252a |
| Description | K-252a is a protein kinase inhibitor targeting serine-threonine, tyrosine, and CAM kinases. In vitro, it blocks NGF-induced TrkA signalling and neural differentiation, exhibiting antitumour, antibacterial, anti-inflammatory, and neuroprotective activities. |
| In vitro | Methods: LINC00641 overexpressing cell lines were treated with K-252a (1.7 nM, 6 hours), and the expression of target proteins in cells was detected by Western blotting.
Results: K-252a can reduce the levels of p-Akt and p-TrkB in LINC00641 overexpressing cell lines. [3]
Methods: PC12 subclone h cells were treated with K-252a (3-100 nM, 8 days) to study its effect on cell viability.
Results: K-252a can inhibit NGF-induced neurite outgrowth. [4] |
| In vivo | Methods: Mice were treated with K-252a (20 mg/kg, intraperitoneal injection, once a day for 5 days) and their neurological function was evaluated. Results: K-252a was able to inhibit the TH-induced neuroprotective effect in mice. [5] |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 40 mg/mL (85.57 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.28 mM), Sonication is recommended.
|
| Keywords | SF-2370 | SF 2370 | PKC | PKA | phosphorylase kinase | K-252a | K252a | K 252a | Ca2+/calmodulin-dependent kinase type II | Antibiotic SF-2370 | Antibiotic SF2370 |
| Inhibitors Related | Neomycin sulfate | Aceglutamide | Hemin | Tamoxifen | Sulfamethoxazole sodium | Terbinafine hydrochloride | Hydroxychloroquine | Metronidazole | Doxycycline | Ethyl linoleate | Paeonol | Alginic acid |
United States
